NeoTract has enrolled first US patients in a multinational trial of its UroLift System at Western Urological Clinic in Salt Lake City, Utah.

The UroLift System, a set of minimally invasive devices designed to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), lifts prostate tissue out of the way so that it no longer blocks the urethra.

The LIFT Study targets male patients ages 50 or older who have urinary problems related to BPH.

The study is being conducted in the US, Canada and Australia in connection with an Investigational Device Exemption to support market approval by the US Food and Drug Administration.

The UroLift system has already received CE mark approval and regulatory approval from the Australian Therapeutic Goods Administration (TGA) and is available for sale in select markets in Europe and Australia.